Of IgM nephropathy patients with MCNS and DMH, a significant percentage develop impaired renal function, due to the evolution of FSGS, as revealed by repeat biopsy during long-term follow up.
Our results suggest that increased plasma ET-1 concentrations may play an important role in the pathogenesis of hypertension in children with acute poststreptococcal glomerulonephritis.
Objective: To examine whether plasma or urine elastase α1-proteinase inhibitor (E-α1-PI) levels could be used as a diagnostic marker of urinary tract infection (UTI) in neonates. Subjects and Methods: Plasma and urine E-α1-PI levels were measured by immunoassay in 23 neonates with UTI at the time of admission and 72 h after the onset of treatment and in 10 ‘normal’ neonates (i.e. with trivial problems). Additionally E-α1-PI plasma levels were measured in 15 neonates with septicemia. Results: E-α1-PI plasma levels did not differ between normal neonates and those with UTI. Urine E-α1-PI levels were significantly higher in neonates with UTI on admission compared to normal neonates. A significant decrease in urine E-α1-PI levels was noticed 72 h after the onset of treatment in all but 2 neonates in whom infection persisted. In this study, we have found that the urine E-α1-PI concentration at a cutoff level of 48 µg/l had a sensitivity of 83%, a specificity of 90%, a positive predictive value of 95% and a negative predictive value of 69% for the diagnosis of neonatal UTI. Conclusion: Elevated levels of E-α1-PI in urine seem to be a useful tool for the diagnosis of UTI in neonates (even in those that have already been started on antibiotics) and possibly a valuable marker for early recognition of treatment failure.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.